Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing [Yahoo! Finance]
Opko Health, Inc. (OPK)
Last opko health, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.opko.com
Company Research
Source: Yahoo! Finance
New data shows up to 61% reduction in healthcare costs for children with neurodevelopmental disorders in the 12 months following ExomeDx™ and GenomeDx™ testing, regardless of the test result GAITHERSBURG, Md., March 11, 2026 BUSINESS WIRE )--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced findings from the Genetic S equencing A nalysis has V alue in E conomic S avings (SAVES)-Kids Study, a real-world data Health Economics and Outcomes Research (HEOR) analysis led by GeneDx that focuses on the economic impact of whole exome sequencing (WES) and whole genome sequencing (WGS) in children with neurodevelopmental disorders, like epilepsy and developmental delay and intellectual disability (DD/ID). The data was unveiled today at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting in Baltimore, MD. The study demonstrates that GeneDx's ExomeDx™ and GenomeDx™ significantly reduce tot
Show less
Read more
Impact Snapshot
Event Time:
OPK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPK alerts
High impacting Opko Health, Inc. news events
Weekly update
A roundup of the hottest topics
OPK
News
- “CNBC CURES: DEFYING RARE DISEASE” WITH BECKY QUICK TO PREMIERE ON THURSDAY, MARCH 19 AT 7PM ET [CNBC]CNBC
- GeneDx Holdings Corp. (WGS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C [Yahoo! Finance]Yahoo! Finance
- GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership [Yahoo! Finance]Yahoo! Finance
- OPKO Health (OPK) had its price target lowered by Barrington Research from $2.25 to $1.50. They now have an "outperform" rating on the stock.MarketBeat
OPK
Earnings
- 2/26/26 - Beat
OPK
Analyst Actions
- 3/2/26 - Barrington Research
OPK
Sec Filings
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- OPK's page on the SEC website